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Background: The number of patients with diabetes or the metabolic syndrome reaches epidemic proportions. On
top of their diabetic cardiomyopathy, these patients experience frequent and severe cardiac ischemia-reperfusion
(IR) insults, which further aggravate their degree of heart failure. Food restriction and angiotensin-converting
enzyme inhibition (ACE-I) are standard therapies in these patients but the effects on cardiac IR injury have never
been investigated. In this study, we tested the hypothesis that 1° food restriction and 2° ACE-I reduce infarct size
and preserve cardiac contractility after IR injury in mouse models of diabetes and the metabolic syndrome.
Methods: C57Bl6/J wild type (WT) mice, leptin deficient ob/ob (model for type II diabetes) and double knock-out
(LDLR-/-;ob/ob, further called DKO) mice with combined leptin and LDL-receptor deficiency (model for metabolic
syndrome) were used. The effects of 12 weeks food restriction or ACE-I on infarct size and load-independent left
ventricular contractility after 30 min regional cardiac ischemia were investigated. Differences between groups were
analyzed for statistical significance by Student’s t-test or factorial ANOVA followed by a Fisher’s LSD post hoc test.
Results: Infarct size was larger in ob/ob and DKO versus WT. Twelve weeks of ACE-I improved pre-ischemic left
ventricular contractility in ob/ob and DKO. Twelve weeks of food restriction, with a weight reduction of 35-40%, or
ACE-I did not reduce the effect of IR.
Conclusion: ACE-I and food restriction do not correct the increased sensitivity for cardiac IR-injury in mouse
models of type II diabetes and the metabolic syndrome.
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The number of patients with diabetes and the metabolic
syndrome increases in Western societies and reaches
epidemic proportions [1,2]. At present, diabetes affects
approximately 250 million people worldwide and by
2025 this is expected to increase to over 380 million,
with type II diabetes accounting for 90-95% of them.
Prevalence is expected to increase most in Asia and Af-
rica with the majority of patients in 2030 being found
there [2]. The prevalence of the metabolic syndrome* Correspondence: paul.herijgers@uzleuven.be
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distribution, and reproduction in any mediumcurrently exceeds 20% of individuals who are over
20 years of age and 40% of the population older than
40 years [1]. Heart failure is the leading cause of mortal-
ity in people with type II diabetes. The incidence of
myocardial infarction in diabetic patients is twice that of
the general population [3,4]. They are at increased risk
for mortality and post-ischemic complications [3,4]. In-
farct size for a given ischemic insult is larger in diabetic
mice than in controls [5-7]. This, on top of diabetic car-
diomyopathy [8,9], contributes to progressive heart fail-
ure. Therefore, new or additional techniques to protect
the diabetic heart against this ischemia/reperfusion (IR)
damage are eagerly awaited.Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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quently used therapies in type II diabetes [10].
Although food restriction is a standard therapy in type
II diabetic patients, no long-term large-scale study of
intentional weight loss has been adequately powered to
examine cardiovascular disease end points in patients
with diabetes [10]. Conflicting data were reported con-
cerning the effect of food restriction on cardiac contract-
ility in experimental models. Some studies in diabetic
mice report a reduced mean 24-hour blood pressure and
heart rate, restored circadian variations of blood pres-
sure and heart rate, and increased ejection fraction [11].
In other studies with obese rats, stroke volume, left ven-
tricular work and cardiac output decreased significantly
after food restriction [12]. Similarly, the effect of food re-
striction on the impact of IR injury was barely investi-
gated. In a study with wild type rats, ex vivo cardiac
contractility was better preserved after IR injury after 8-
months of food restriction [13]. The effect of food re-
striction on IR injury in diabetic or metabolic syndrome
models was never investigated.
Current guidelines advocate ACE-inhibitors as the
drugs of choice in the initial treatment of hypertension
in diabetic patients [10]. ACE-I is favored because, in
addition to the blood pressure lowering properties, it
has well documented anti-ischemic and anti-atherogenic
effects, reduces oxyradical formation and has an effect
on cardiovascular remodeling. ACE-I improves glucose
control and insulin sensitivity and slows the progression
of diabetic nephropathy [14]. In a large meta-analysis of
patients with acute myocardial infarction, ACE-I
reduced 30-day mortality from 7.6 to 7.1% and in the
subgroup of diabetic patients from 12.0 to 10.3% [15].
The effect of ACE-I in experimental models of acute
IR injury is uncertain [16-21]. Experiments with capto-
pril in a canine, porcine and rat model report a reduced
myocardial injury although other experiments in canine
models do not show any effect [16,17]. Studies with
other ACE-inhibitors report also heterogeneous data.
Some report a reduction in infarct size [18,19] while
others see no effect [20]. In Langendorff-perfused mouse
hearts, captopril has no beneficial effect on post-
ischemic contractile recovery or cardiac enzyme release
[21]. Nevertheless, when cardiac p90 ribosomal S6 kin-
ase is over-expressed in mice, captopril induces a better
post-ischemic contractility and reduced enzyme release
[21]. Since p90 ribosomal S6 kinase is activated in hyper-
glycemic mice, it might be possible that captopril
induces protection in diabetic mice models.
Therefore, the aim of this study is to investigate the
effects of food restriction and ACE-I on IR injury in dia-
betic or metabolic syndrome models. We tested the hy-
potheses that 1° food restriction and 2° ACE-I do correct
the increased sensitivity for cardiac IR injury.Methods
Animal models
Experiments were conducted in C57BL/6J WT-mice,
leptin deficient ob/ob, and double knock-out (DKO)
mice with combined leptin and LDL-receptor deficiency
(total number = 145). The ob/ob mouse is a model for
type II diabetes, featuring abdominal obesity and insulin
resistance. DKO mice feature many characteristics of the
metabolic syndrome, i.e. obesity, dyslipidemia, hyperten-
sion, insulin resistance and impaired glucose tolerance
and/or diabetes [8,11]. These models develop left ven-
tricular diastolic and systolic dysfunction comparable
with the diabetic cardiomyopathy seen in patients [8].
Ob/ob and C57BL/6J mice were purchased from Jack-
son Laboratory (Bar Harbor, Maine, USA). DKO were
generated as described previously [8,11]. IR was induced
at 24 weeks of age. The investigation conforms with the
Guide for the Care and Use of Laboratory Animals pub-
lished by the US National Institutes of Health (NIH Pub-
lication 1996). All experimental protocols were approved
by the K.U.Leuven Institutional Animal Care Commis-
sion and Ethical Committee.
Treatments
Food intake of diet-restricted ob/ob and DKO mice was
restricted to 2.5 g/day, which is the normal daily intake
of lean WT mice, between 12 and 24 weeks of age [11].
ACE-inhibition was obtained with captopril (10 mg/kg/
day) intraperitoneally from 12 until 24 weeks of age in
WT, ob/ob and DKO [22].
Biochemical analysis
Blood of conscious mice was collected by tail bleeding
into EDTA tubes after a 24 h fast at 12 and 24 weeks of
age. Plasma was obtained by centrifugation. Triglycerides
and total cholesterol was determined with a diagnostic
reagent kit (Roche) and glucose with a glucometer
(Menarini Diagnostics).
Ischemia/reperfusion
The experimental technique was previously described
[23]. Briefly, anesthesia was induced with urethane
(1.2 g/kg) and alfa-chloralose (50 mg/kg). Mice were
ventilated with room air, with rectal temperature kept at
37 ± 0.5°C. Via left thoracotomy, the left anterior des-
cending artery (LAD), was non-traumatically occluded,
2 mm below the tip of the left auricle for 30 min. After-
wards, a reperfusion period of 1 hour was allowed. Suc-
cessful coronary occlusion and reperfusion was visually
verified by observing the myocardium distal to the cor-
onary occlusion turning pale respectively blushing. In
the groups without ischemia (sham), a thoracotomy and
time-matched procedure was performed.
Van der Mieren et al. Cardiovascular Diabetology 2012, 11:89 Page 3 of 10
http://www.cardiab.com/content/11/1/89Outcome parameters: infarct size and in vivo left
ventricular contractility
The technique was previously described [23]. At the end
of 1 hour reperfusion, a pressure-conductance catheter
(1.4-Fr, SPR-839; Millar Instruments, Houston, TX) was
inserted through the right carotid artery into the left
ventricle. Baseline pressure-volume (PV) loops were
recorded (Powerlab/AD Instruments, Castle Hill, Aus-
tralia). Parallel volume and specific blood conductance
were determined [8,23]. The inferior caval vein was
compressed to obtain left ventricular PV-loops under
varying loading conditions. Heart rate, systolic and end-
diastolic pressure were measured. Stroke volume was
determined as the difference in end-diastolic and end-
systolic volume. Stroke work (SW) is the mechanical en-
ergy which the heart develops during the cardiac cycle
and is calculated as the area enclosed by the PV-loop.
Preload recruitable stroke work (PRSW) is the slope of
the relationship between end-diastolic volume and SW
performed by the ventricle. PRSW is the most reliable
and useful parameter for general contractility since it is
chamber size independent and robust [24]. The slope of
the end-systolic pressure-volume relationship, end-
systolic elastance (Ees), reflects left ventricular chamber
end-systolic stiffness and is used as an index of contract-
ility. Tau is the time constant of left ventricular relax-
ation during isovolumetric diastole. The end-diastolic
PV-relationship (EDPVR) represents the compliance of
the ventricular myocardium at the end of the diastole.
Augmented stiffness of the ventricular wall increases the
slope of the EDPVR. Arterial elastance (Ea), a measure
for afterload, is defined as the end-systolic pressure to
stroke volume ratio [23,24].
Before excision of the heart, Evans blue (0.8 ml, 1% so-
lution) was injected intravenously after re-occlusion of
the LAD, to determine the left ventricular perfusion areaTable 1 Metabolic parameters
Genotype Age
(weeks)
Treatment Weight (g) Hea
tibial le
Wild type 12 Untreated 21.1 ± 3.1
24 Untreated 28.5 ± 4.4 74
Ob/ob 12 Untreated 49.5 ± 3.5a
24 Untreated 62.7 ± 3.7a 76
24 Diet 38.5 ± 4.4ac 71
24 ACE-I 64.1 ± 9.4ad 74
DKO 12 Untreated 47.0 ± 2.4a
24 Untreated 59.4 ± 9.3a 79
24 Diet 38.2 ± 3.6ac 68
24 ACE-I 64.0 ± 8.0ad 70
“a” p< 0.05 versus WT, same age, untreated; “b”p< 0.05 versus ob/ob, same age, sam
“d” p< 0.05 versus diet, same genotype, same age.at risk. The heart was cut in 1 mm-slices and the slices
were stained with triphenyl-tetrazolium-chloride solu-
tion (TTC, 20 min, 1%, 37°C, pH 7.4) and fixed in paraf-
ormaldehyde (10 min, 4% solution, 20°C). All slices were
weighed and photographed with a digital camera under
magnification.
Data management and statistical analysis
Analysis of the pressure-conductance data was per-
formed using PVAN 3.2 software (Millar Instruments,
Houston) as previously described [8,23].
Infarct size and area at risk were determined by the
number of pixels in each zone with Adobe Photoshop
8.0 (Adobe System Inc.) multiplied by the weight of the
respective slices.
All statistical analyses were performed using Statistical
software (Statistica 7.1, StatSoft, Tulsa, USA). Data are
expressed as mean ± standard deviation. Differences be-
tween groups were analyzed for statistical significance by
Student’s t-test or factorial ANOVA followed by a Fish-
er’s LSD post hoc test. A value of p < 0.05 was consid-
ered significant.
Results
Biochemical parameters and contractility in untreated
mice
Untreated ob/ob and DKO have a significantly higher
weight and exhibit hyperglycemia (Table 1). Cholesterol
levels are elevated in ob/ob and even higher in DKO.
DKO also have increased triglycerides levels. Left ven-
tricular contractility, expressed as PRSW, is worse in ob/
ob than in WT and even worse in DKO (Figure 1). Dia-
stolic function, represented by end-diastolic pressure
and EDPVR, is significantly worse in DKO than in WT
(Table 2). Ejection fraction is not reported since it is








56.2 ± 6.5 104 ± 70 115± 42
.1 ± 9.0 71.2 ± 11.8 76 ± 14 60 ± 14
163 ± 73a 125 ± 20 58 ± 11a
.6 ± 7.7 166 ± 41a 139 ± 35a 68 ± 12
.8 ± 7.1c 142 ± 63a 74 ± 24c 69 ± 15
.8 ± 9.1 84 ± 19acd 145 ± 34ad 76 ± 13a
155 ± 47a 912 ± 188ab 591± 181ab
.3 ± 13.4 152 ± 108a 749 ± 114ab 245± 80ab
.0 ± 8.5ac 141 ± 62a 754 ± 123ab 252± 110ab
.3 ± 7.2c 124 ± 36ab 658 ± 166ab 202± 67ab
e treatment; “c” p< 0.05 versus same untreated genotype , same age;
Figure 1 Preload recruitable stroke work in wild type, ob/ob
and double knock-out mice. “a” p< 0.05 versus WT same treatment,
same age; “b” p< 0.05 versus same untreated genotype, same age;
“c” p< 0.05 versus sham, same genotype, same treatment; “d” p< 0.05
versus diet, same genotype, same age“e” p< 0.05 versus ob/ob same
treatment, same age.
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mice [9].Effect of IR
The area at risk after coronary occlusion is comparable
in all groups (Table 3). As expected, none of the sham
groups showed an infarct. After IR, infarct size was lar-
ger in DKO and ob/ob versus WT (Figure 2). After IR,
PRSW decreased significantly in all groups and was sig-
nificantly lower in DKO and ob/ob versus WT
(Figure 1).Effect of food restriction on biochemical parameters and
contractility
Food restriction resulted in lower body and heart weight
in both ob/ob and DKO (Table 1). Heart weight was
even lower in food restricted DKO than in WT. Food re-
striction had little effect on biochemical parameters.
Food restriction did not improve the reduced PRSW in
ob/ob and DKO mice (Figure 1).Effect of food restriction on IR injury
Food restriction did not reduce infarct size in DKO nor
ob/ob versus the untreated groups (Figure 2). The im-
pact of IR on PRSW was not influenced by food restric-
tion (Figure 1).
Effect of ACE-I on biochemical parameters and
contractility
ACE-I reduced glycemia levels in ob/ob but much less
in DKO (Table 1). Heart weight, was lower in DKO but
not in ob/ob after ACE-I compared with the untreated.
PRSW was significantly better after 12 weeks of ACE-I
in ob/ob and DKO versus diet (Figure 1, Table 2).
Effect of ACE-I on IR injury
ACE-I did not reduce infarct size in any genotype versus
the untreated groups (Figure 2). Furthermore, ACE-I did
not reduce the impact of IR on PRSW in any genotype
(Figure 1).
Discussion
The number of patients with diabetes and the metabolic
syndrome reaches epidemic proportions [1,2]. The inci-
dence of myocardial infarction in diabetic patients is
twice that of the general population [3,4]. Infarct size for
a given ischemic insult is larger in diabetic patients than
in non-diabetic patients [3,4]. This, on top of diabetic
cardiomyopathy [8,9], contributes to progressive heart
failure. Therefore, new or more potent strategies to pro-
tect them against cardiovascular complications are
needed. Our mice models of type II diabetes and the
metabolic syndrome are, similar to the clinical reality,
more vulnerable for IR injury. In other experimental dia-
betic models, disagreement exists about the sensitivity to
IR injury [25-28]. Depending on the reports, infarct size
in animal models of diabetes was larger, smaller or simi-
lar to non-diabetic controls [26]. There are numerous
differences in experimental protocols and a single factor
cannot entirely explain the discrepancies. Duration of
the diabetic state and plasma level of insulin (type I ver-
sus type II) seems to influence the myocardial suscepti-
bility to IR injury [26]. Although type II diabetes
represents 90% of the diabetic patients, the majority of
the experimental studies are performed in type I diabetic
rat models, induced by streptozotocin [5,25-27]. Most of
them report a similar or reduced myocardial infarct area
after IR injury [25,26]. Rodrigues et al. [25] reported
that 3 months after IR injury, also ventricular dysfunc-
tion was attenuated and the profile of calcium handling
proteins was better. Nevertheless, the mortality was
higher in the type I diabetic group, due to increased
autonomic dysfunction [25]. The sensitivity to IR injury
in this model seems to be time-dependent. Some studies
report a resistance to IR early after diabetes induction by
Table 2 Hemodynamic parameters
Condition Wild type Ob/ob DKO
Sham IR Sham IR Sham IR
Heart rate (bpm) Untreated 575± 40 560±62 526 ± 44a 540±41 523 ± 29a 513±38
Diet 504 ± 30a 500 ± 31 503 ± 34a 516±51
ACE-I 548 ± 33 524 ± 36 505 ± 29 492±33 499 ± 51 509±68
Stroke volume (μl) Untreated 16.2 ± 5.3 6.8±3.2c 14.8 ± 3.1 12.0±4.3a 10.1 ± 5.1a 9.6±4.1
Diet 13.6 ± 6.0 14.2±7.0a 11.8 ± 5.1 12.7±6.1a
ACE-I 16.5 ± 4.9 8.1 ± 1.6c 14.0 ± 3.2 12.6±4.2a 15.1 ± 6.1 12.4±3.0a
Stroke work (mmHg*μl) Untreated 1256± 328 263±167c 835 ± 189a 509±181ac 606 ± 269a 409±199
Diet 804 ± 546 667±336a 627 ± 272a 676±332a
ACE-I 877 ± 399 369 ± 158c 788 ± 251 581±230 780 ± 408 563±170
Psys (mmHg) Untreated 80.5 ± 18.2 55.1±10.6
c 68.7 ± 7.5 62.5±2.7 69.5 ± 11.1 62.7±10.6
Diet 68.4 ± 10.8 60.4±5.9 67.1 ± 12.6 65.0±5.5a
ACE-I 62.9 ± 11.9 61.9 ± 19.9 67.9 ± 6.9 59.2±7.5c 61.4 ± 6.2 56.1±8.1d
Ped (mmHg) Untreated 3.0 ± 0.7 2.9±1.2 3.6 ± 0.7 6.6±3.3
ac 4.8 ± 2.3a 6.6±2.4a
Diet 3.0 ± 1.1 4.3±1.2a 3.8 ± 1.3 4.3±1.5ab
ACE-I 3.6 ± 2.0 2.9 ± 2.3 4.5 ± 0.9d 5.0±1.5 3.7 ± 0.9 3.4±1.5b
PRSW (mmHg) Untreated 88.8 ± 5.5 61.5 ± 11.6c 64 ± 2.6a 48.5 ± 3.3ac 57.1 ± 4.6ae 46.2 ± 8.8ac
Diet 65.4 ± 1.9a 51 ± 1.9ac 58 ± 2.8ae 49.7 ± 3ac
ACE-I 87.4 ± 4.4 60.2 ± 6.4c 71.8 ± 3.2abd 52.1 ± 3.4ac 66.3 ± 5abde 51.2 ± 3.4ac
Ees (mmHg/μl) Untreated 8.3 ± 2.5 6.4±1.5 5.1 ± 0.4
a 4.7±1.5 6.5 ± 2.4 4.5±0.8a
Diet 6.6 ± 2.1 4.5±1.1ac 5.1 ± 1.2a 5.3±1.2
ACE-I 6.0 ± 1.0 6.8 ± 2.0 5.5 ± 1.7 4.6±1.7 5.6 ± 1.3 4.4±1.3a
Tau (ms) Untreated 6.3 ± 1.2 7.6±2.2 6.2 ± 0.5 6.4±1.0 6.9 ± 0.9 7.2±0.7
Diet 6.9 ± 0.5b 7.7±0.8bc 6.8 ± 0.6 7.3±1.2
ACE-I 6.6 ± 1.5 7.4 ± 1.5 8.0 ± 1.1bd 8.8±1.5b 7.4 ± 0.8 7.1±1.1e
EDPVR (mmHg/μl) Untreated 0.2 ± 0.2 0.4±0.2 0.4 ± 0.3 0.5±0.3 0.6 ± 0.4a 0.3±0.1
Diet 0.2 ± 0.2 0.2±0.1 0.2 ± 0.2 0.2±0.1ab
ACE-I 0.2 ± 0.1 0.4 ± 0.3 0.4 ± 0.1 0.3±0.1 0.3 ± 0.1be 0.3±0.1d
Ea (mmHg/μl) Untreated 4.8 ± 1.5 8.1 ± 2.4
c 4.0 ± 0.9 5.0±2.0a 6.8 ± 3.5 5.6±1.8a
Diet 4.9 ± 1.8 4.8±2.7a 5.2 ± 2.2 5.4±2.1a
ACE-I 3.3 ± 0.6b 6.9 ± 1.3c 4.6 ± 1.5 4.5±1.5a 3.4 ± 1.3b 3.8±1.0ab
ACE-I: angiotensin-converting enzyme inhibition; DKO: double knock-out (ob/ob; LDLR-/-); Ea: arterial elastance; EDPVR: end-diastolic pressure-volume relationship;
Ees: end-systolic elastance; IR: ischemia/reperfusion; Ped: end-diastolic pressure; Psys: systolic pressure
“a” p< 0.05 versus WT same treatment, same condition (sham
or IR); “b” p< 0.05 versus same untreated genotype, same condition (sham or IR); “c” p< 0.05 versus sham, same genotype, same treatment; “d” p < 0.05 versus diet,
same genotype, same condition (sham or IR); “e” p< 0.05 versus ob/ob same treatment, same condition (sham or IR).
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Others however demonstrated an increased infarct size
after coronary occlusion as early as 8 days after strepto-
zotocin injection [26], indicating that duration of dia-
betes is not the only factor responsible for the
heterogeneous results. Disagreement also exists about
the effect of acute hyperglycemia to IR injury. Although
some studies report a larger or similar susceptibility to
IR injury in a hyperglycemic state, other reports demon-
strate a significant protection, related to a better profile
of calcium handling proteins [25,26].The difference in presence or absence of hyperinsuli-
nemia may also be responsible for the heterogeneous
data. With the exceptions of a few studies in type II dia-
betic Zucker and Goto-Kakizaki rats, all type II diabetic
models with obesity and hyperinsulinemia showed
increased myocardial susceptibility to IR injury [26]. In
the past decade, transgenic mouse models of type II dia-
betes and the metabolic syndrome have been developed.
These models develop left ventricular diastolic and sys-
tolic dysfunction comparable with the diabetic cardio-
myopathy seen in patients [8]. We demonstrated in this
Table 3 Numbers and infarct size
Condition Wild type Ob/ob DKO
Sham IR Sham IR Sham IR
N experiments (survivors) Untreated 9 (9) 12 (10) 7 (7) 11 (6) 7 (7) 9 (7)
Diet 9 (7) 11 (7) 9 (7) 9 (8)
ACE-I 6 (6) 8 (6) 10 (8) 10 (8) 8 (8) 10 (8)
Area at risk (% of heart) Untreated 0 ± 0 14.7 ± 7.5 0 ± 0 14.0 ± 6.7 0 ± 0 18.2 ± 7.2
Diet 0 ± 0 17.8 ± 3.4 0 ± 0 16.4 ± 8.6
ACE-I 0 ± 0 17.0 ± 7.1 0 ± 0 17.1 ± 3.4 0 ± 0 15.3 ± 5.6
Infarct size (% of area at risk) Untreated 0 ± 0 49.3 ± 6.8b 0 ± 0 72.4 ± 7.2ab 0 ± 0 67.2 ± 6.1ab
Diet 0 ± 0 68.4 ± 9.8ab 0 ± 0 70 ± 11.9ab
ACE-I 0 ± 0 55.1 ± 5.7b 0 ± 0 69 ± 8.1ab 0 ± 0 68.8 ± 9.9ab
ACE-I: angiotensin-converting enzyme inhibition; DKO: double knock-out (ob/ob; LDLR-/-); a” p< 0.05 versus WT same treatment, same condition (sham or IR);
“b” p< 0.05 versus sham, same genotype, same treatment.
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metabolic syndrome are more vulnerable for IR injury
than their WT littermates. This correlates well with data
from patient studies and previous studies in transgenic
mice with type II diabetes [6,7,26]. Nevertheless, theFigure 2 Infarct size as % of risk zone in wild type, ob/ob and
double knock-out mice. “a” p< 0.05 versus WT same treatment,
same age; “b” p< 0.05 versus same untreated genotype, same age;
“c” p< 0.05 versus sham, same genotype, same treatment; “d” p< 0.05
versus diet, same genotype, same age; “e” p< 0.05 versus ob/ob
same treatment, same age.underlying mechanisms by which type II diabetic and
metabolic syndrome myocardium is more vulnerable to
IR injury remains incompletely understood. Several hy-
potheses were suggested.
First, the diabetic myocardium exhibits abnormal car-
diac substrate utilization and impaired energetic effi-
ciency. In non-ischemic conditions, the myocardium
uses preferentially fatty acids as energy substrate. This is
even more the case in type II diabetes and the metabolic
syndrome. The use of fatty acids requires 12% more
oxygen per ATP generated than glucose. During ische-
mia, the normal myocardium switches to glucose as pre-
ferred energy substrate. This possibility is lost in case of
diabetes, because oxidation of fatty acids inhibits the ca-
tabolism of glucose [29].
Second, endothelial dysfunction and reduced nitric
oxide (NO) bioavailability is present in type II diabetes
and the metabolic syndrome [11,14]. The beneficial or
detrimental effect of NO depends on its concentration
and cellular origin [5]. Although constitutive production
of NO by endothelial cells (eNOS) is thought to be cyto-
protective, NO generated by the inducible form (iNOS)
is generally regarded as pro-inflammatory and cytotoxic.
In diabetic myocardium, basal iNOS-levels are higher
and the increase of iNOS-levels after IR injury is larger
than in non-diabetic myocardium [30].
Third, SERCA2a is crucial in postischemic myocardium
by significantly decreasing intracellular Ca2+-overload
[31]. It was shown before that SERCA2a-activity is
depressed in ob/ob and DKO mice [8]. In the streptozo-
tocin type I diabetic model, SERCA2a-expression after IR
injury is increased versus WT animals. This is a possible
explanation for the better preserved contractility after IR
injury in this model [25].
Fourth, diabetic and metabolic syndrome models ex-
hibit increased production of reactive oxygen spe-
cies (ROS) [32]. ROS likely plays a central role in
impairing mitochondrial energy metabolism, through
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age of mitochondrial components. This can lead to
apoptosis [32].
Fifth, the activity of aldose reductase, a NADPH-
dependent enzyme, increases during IR injury [33]. Since
aldose reductase activity is already increased in diabetes
[34], IR injury further reduces myocardial glycolysis and
glucose oxidation and increases the glycosylation of
advanced end-products. This leads to more extensive
cross-linking of key structures within tissues and
increased IR injury [34].
Sixth, chronic hyperglycemia leads to cardiac hyper-
trophy and decreased microvasculature density in myo-
cardium. This microcirculation dysfunction causes
increased vulnerability to IR [28].
Seventh, the exposure to abnormal substrates and
cytokines makes the diabetic heart more prone to IR. It
was recently shown that IL-33 is decreased in type I dia-
betic mice [28]. It is known that IL-33 prevents apop-
tosis, attenuates myocardial infarction and improves
cardiac function. In this study was also shown that
chronic activation of protein kinase C-β in diabetes con-
tributes to myocardial dysfunction and infarct [28].
Finally, leptin deficiency leads to ventricular hyper-
trophy and heart failure [35,36]. McGaffin et al. reported
that leptin has a protective role after IR [36]. Leptin defi-
cient mice had worse survival, worse cardiac function
and increased apoptosis, 4 weeks after IR injury. Leptin
induces activation of signal transducer and activator of
transcription-3, which induces transcription of several
cardioprotective genes. These, in turn, inhibit reverse re-
modeling and apoptosis [35,36]. It is thus possible that
leptin deficiency leads to reduced contractility and larger
infarct size versus WT, independently from the other
risk factors. Nevertheless, the effect of leptin deficiency
during the acute phase of IR, as in our experiments, is
not known. It is unlikely that STAT-3 activation plays a
role during the first hours after IR injury, since tran-
scription of new cardioprotective genes is required.
In hypothesis 1 and 2, we postulated that food restric-
tion respectively ACE-I could reduce the effects of IR in-
jury in mouse models of type II diabetes and the
metabolic syndrome. In our study, 12 weeks food restric-
tion or ACE-I, was not capable to preserve in vivo car-
diac contractility, nor limit infarct size after IR injury.
Nevertheless, ACE-I significantly improved load-
independent contractility, as measured by PRSW, in the
non-ischemic group.
In food restricted mice, the daily intake was limited to
the amount of ‘normal’ free fed wild type mice, mea-
sured to be 2.5 g/day. After 12 weeks, the weight loss of
ob/ob and DKO mice was 35 à 40% of initial body
weight. We did find a slight but non-significant restor-
ation of contractility after this treatment. In a previousstudy by our group [37], we found that food restriction
with body weight reduction of 50 à 55%, partly restored
contractility. So, it is possible that weight reduction of
35 to 40% is insufficient to significantly improve con-
tractility in our mice models. Nevertheless, heart weight
was reduced in ob/ob and even more in DKO, below the
level of WT, demonstrating already the impact of the
food restriction. A further explanation for the difference
between the present and earlier studies is that the ex-
perimental conditions in the present study differed from
the previous. In the study of Van den Bergh et al. [37],
hemodynamic measurements were performed in closed
chest mice. In this study, an IR protocol was investi-
gated. This implicates that also in the control groups,
left ventricular contractility was measured in the same
experimental conditions as the ischemia-reperfusion
group, i.e. with an open thorax and time matched.
Food restriction has been shown to reduce IR injury in
wild type rodent models [13,38,39]. In renal IR injury,
30% food reduction leads to significant protection. The
length of restriction, required for the onset of these renal
benefits, is not known but also food restrictions, as little
as 2 weeks, lead to significant protection. Interestingly,
there is no increase in protection between 2 and 4 weeks
of food restriction, suggesting that the maximal protec-
tion afforded by these short treatments was already
reached after 2 weeks [38]. Also in the heart, different
short-term (2 weeks) food restriction protocols, ranging
from 10% to 70%, improve cardiac function following IR
injury in wild type rats [39]. Yamagishi et al. [39]
reported that 70% food restriction during 11 days, result-
ing in a weight reduction of 38% compared to free-fed
rats, has a different effect on pre-ischemic contractility
and sensitivity to IR injury. In this study, pre-ischemic
cardiac function was reduced but cardiac recovery after
IR injury was improved [39]. An improved ischemic tol-
erance via altered expression of functional proteins
induced by low serum T3 levels, decreased coronary
flow rate and change in metabolic flux, were suggested.
Anaerobic glycolysis was more activated during ischemia
in food restricted animals. This activation of glycolytic
flux is fundamental to effective recovery of cardiac func-
tion during reperfusion after ischemia [39]. Nevertheless,
the boundary between food restriction and under nutri-
tion is weak. More than 70% food restriction results in
depressed cardiac function [39]. The effect of food re-
striction on IR injury was never studied in the intended
group, the obese type II diabetic patients and animal
models. In our type II diabetic and metabolic syndrome
mouse models, food restriction did not induce signifi-
cant protection against IR injury.
The effects of food restriction and ACE-I on the previ-
ously described mechanisms of increased vulnerability of
type II diabetic myocardium to IR injury are incompletely
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cardiac substrate utilization, energetics or aldose reductase
activity are missing. Dyslipidemia seems to be a less im-
portant factor during IR injury, since infarct size and left
ventricular contractility were not significantly different in
DKO mice versus ob/ob. Although cholesterol-levels were
normal after food restriction in ob/ob mice, this could not
correct the increased sensitivity to IR injury.
ACE-I prevents downregulation of SERCA2a and phos-
pholamban protein expression in heart failure [40]. Fur-
thermore, ACE-I prevents the decrease in capillary
density in type I diabetic rats [41]. This might explain
the improved contractility in ob/ob and DKO mice with
ACE-I.
It is widely accepted that food restriction and ACE-I
reduce oxidative stress [13,14]. Nevertheless, nor food
restriction nor ACE-I were capable to reduce IR injury
in our mice models. This casts doubt on the role of oxi-
dative stress in the increased vulnerability of diabetic
myocardium to IR injury. No data are available concern-
ing the effects of food restriction on capillary density,
abnormal substrate utilisation or cytokinelevels in dia-
betic models.
Captopril has been reported to reduce infarct size in
animal models, such as canine, porcine or rat models
[16,17]. In the study of Itoh et al. [21], captopril did not
protect WT mice against post-ischemic dysfunction and
myocardial enzyme release. In contrast to this, a signifi-
cant protection by captopril was found in mice with
overexpression of p90 ribosomal S6 kinase. Since p90
ribosomal S6 kinase expression and activity are
increased in diabetic mice, a protective effect of capto-
pril was anticipated by Itoh et al. [21]. Nevertheless, we
did not find infarct size reduction in our models of type
II diabetes and the metabolic syndrome.
In this study, we investigated the effects of food re-
striction and ACE-I, because these treatments are stand-
ard therapies in type II diabetic and metabolic syndrome
patients. Several other drugs with possible cardioprotec-
tive effects during IR injury have been developed. Per-
oxisome proliferator-activated receptor-γ agonists, such
as rosiglitazone, have been shown to possess insulin-
sensitizing and lipid-lowering and anti-inflammatory
properties [42]. It has been demonstrated that peroxi-
some proliferator-activated receptor-γ agonists reduce
IR injury in wild type and hypercholesterolemic models
[42]. Nevertheless, it was shown by Ren et al. that the
vasculoprotective effects of rosiglitazone are at least par-
tially mediated by a reduction in local angiotensin II
concentration [42]. Since ACE-inhibitors have similar
effects on angiotensin II concentration and recent meta-
analysis suggest that there is an increase in the risk of
myocardial infarction, rosiglitazone was not investigated
in this study [42].Sulfonureas, such as metformin, are insulin-sensitizing
agents, which reduce infarct size in non-diabetic animals
by activation of cAMP-activated protein kinase and Akt.
However, clinical and experimental studies in diabetic
patients and models report a significantly higher cardio-
vascular risk and controversial effects on the effect on IR
injury [26].
Recent evidence has indicated a possible importance
of the endothelin system in the pathogenesis of diabetic
complications [27]. Endothelin receptor blockade limits
myocardial contractile depression in type I diabetic
models [27]. The effect on IR injury was not studied.
Since angiotensin II stimulates and bradykinin decreases
endothelin-1 formation, it is conceivable that the major-
ity of endothelin-1 formation is blocked by ACE-I. Fur-
thermore, endothelin-receptor antagonism additional to
ACE-I has no added benefit against cardiac dysfunction
in type I diabetic rats [27].
Recently, Ichinomiya et al. demonstrated that high-dose
fasudil, a Rho-kinase inhibitor, preserves postconditioning
under acute hyperglycemic state in rats [43]. Rho-kinase
activity is involved in diabetic endothelial dysfunction and
regulation of Rho-kinase signaling is important for cellular
function, such as contraction, mortality, proliferation and
apoptosis. Correspondingly, Rho-kinase is known to be
activated in ischemic myocardium. Inhibition of Rho-
kinase activity is a matter of interest on myocardial pro-
tection against IR injury since it activates the ATP-
sensitive potassium channels [43]. The effect of fasudil on
postconditioning and IR injury in chronic hyperglycemic
states, such as diabetes, has to be determined.
Limitations
We used Captopril as ACE-I. Other ACE-inhibitors,
with different lipid solubility and/or tissue specificity,
might have affected the impact of IR injury. In this
study, we investigated the acute effects of IR injury after
an ischemia/reperfusion time of respectively 30 and 60
minutes. It is possible that the beneficial effects of these
treatments appear in a later phase, for example during
the remodeling phase.
The combination of food restriction and ACE-I was
not investigated. In ob/ob mice, food restriction reduces
weight and cholesterol levels and ACE-I reduces gly-
cemia. It is possible that the combination of these effects
improves myocardial damage. In DKO mice the add-
itional effect is unlikely, since there was no reduction of
cholesterol after diet and only moderate reduction of
glycemia after ACE-I. Further studies have to be con-
ducted to study these effects.
Conclusion
Our mice models of type II diabetes and the metabolic
syndrome are more sensitive to IR injury than their WT
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size and worse in vivo cardiac contractility after 30 min
ischemia followed by 60 min reperfusion. This mimics
the clinical situation of patients with type II diabetes or
the metabolic syndrome.
Twelve weeks of food restriction, with a weight reduc-
tion of 35 à 40%, did not alter left ventricular pre-
ischemic contractility. Nevertheless, twelve weeks of
ACE-I ameliorated contractility in the pre-ischemic ob/
ob and DKO group significantly.
Food restriction and ACE-I did not correct the
increased sensitivity for IR injury in our mice models of
type II diabetes and the metabolic syndrome.
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